Use the hyperlinks, where available to access additional clinical trial information.
Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations
Australian Genomic Cancer Medicine Centre
Other Non-Commercial Sponsor
University of Sydney
Trastuzumab emtansine will be administered intravenously at a dose of 3.6 mg/kg every 21 days continuously until disease progression is documented, the patient experiences an intolerable toxicity, or withdraws for another reason.